Nuveen
IRWD icon

Nuveen’s Ironwood Pharmaceuticals IRWD Stock Holding History

Nuveen’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
355,372
+121,960
+52% +$470K ﹤0.01% 2730
2026
Q1 		$819K Buy
233,412
+93,925
+67% +$385K ﹤0.01% 2666
2025
Q4 		$470K Buy
+139,487
New +$362K ﹤0.01% 2901
2025
Q2 		– Sell
-471,361
Closed -$693K – 3331
2025
Q1 		$693K Buy
471,361
+66,007
+16% +$157K ﹤0.01% 2790
2024
Q4 		$1.8M Hold
405,354
– – ﹤0.01% 2429
2024
Q3 		$1.67M Sell
405,354
-54,087
-12% -$291K ﹤0.01% 2505
2024
Q2 		$3M Sell
459,441
-1,383,802
-75% -$9.79M ﹤0.01% 2187
2024
Q1 		$16.1M Buy
1,843,243
+6,918
+0.4% +$83.9K ﹤0.01% 1311
2023
Q4 		$21M Buy
1,836,325
+706,218
+62% +$6.99M 0.01% 1129
2023
Q3 		$10.9M Sell
1,130,107
-582,623
-34% -$5.71M ﹤0.01% 1428
2023
Q2 		$18.2M Buy
1,712,730
+107,634
+7% +$1.16M 0.01% 1126
2023
Q1 		$16.9M Sell
1,605,096
-204,093
-11% -$2.29M 0.01% 1157
2022
Q4 		$22.4M Buy
1,809,189
+97,790
+6% +$1.11M 0.01% 960
2022
Q3 		$17.7M Sell
1,711,399
-536,357
-24% -$6.08M 0.01% 1101
2022
Q2 		$25.9M Buy
2,247,756
+28,183
+1% +$332K 0.01% 867
2022
Q1 		$27.4M Buy
2,219,573
+115,934
+6% +$1.33M 0.01% 993
2021
Q4 		$23.2M Sell
2,103,639
-192,522
-8% -$2.36M 0.01% 1131
2021
Q3 		$28.4M Sell
2,296,161
-11,444
-0.5% -$148K 0.01% 1028
2021
Q2 		$29.7M Buy
2,307,605
+910,801
+65% +$10.4M 0.01% 1081
2021
Q1 		$15.6M Buy
1,396,804
+527,067
+61% +$5.57M 0.01% 1502
2020
Q4 		$9.91M Sell
869,737
-220,206
-20% -$2.41M ﹤0.01% 1718
2020
Q3 		$9.8M Sell
1,089,943
-400,350
-27% -$3.98M ﹤0.01% 1540
2020
Q2 		$15.4M Buy
1,490,293
+500,309
+51% +$5.12M 0.01% 1209
2020
Q1 		$9.99M Buy
989,984
+387,960
+64% +$4.56M ﹤0.01% 1294
2019
Q4 		$8.01M Sell
602,024
-415,725
-41% -$4.58M ﹤0.01% 1724
2019
Q3 		$8.74M Buy
1,017,749
+92,092
+10% +$895K ﹤0.01% 1655
2019
Q2 		$10.1M Buy
+925,657
New +$10.4M ﹤0.01% 1605

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's IRWD Position: Q2 2026 in Review

Nuveen increased its Ironwood Pharmaceuticals (IRWD) stake by 52% in Q2 2026, buying an estimated $470K and bringing the position to 355,372 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

Nuveen first reported a position in IRWD in Q2 2019 and has held it in 27 quarters since. The position peaked at $29.7M in Q2 2021. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Nuveen held 355,372 shares of Ironwood Pharmaceuticals worth $1.5M as of Q2 2026.
  • Nuveen bought 121,960 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $470K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2730 holding.
  • Nuveen first reported a position in Ironwood Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
  • Nuveen's Ironwood Pharmaceuticals position peaked at $29.7M in Q2 2021.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.